Short Interest in BioNxt Solutions Inc. (OTCMKTS:BNXTF) Grows By 290.0%

Key Points

• BioNxt Solutions Inc. experienced a significant increase in short interest in August, rising 290.0% from 1,000 shares to 3,900 shares.
• The company's stock opened at $0.72, with a market capitalization of $83.19 million and a price-to-earnings ratio of -17.97.
• BioNxt recently reported earnings of ($0.01) EPS for the quarter ending August 28th.

BioNxt Solutions Inc. (OTCMKTS:BNXTF - Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 3,900 shares, anincreaseof290.0% from the July 31st total of 1,000 shares. Based on an average daily volume of 7,700 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily volume of 7,700 shares, the days-to-cover ratio is currently 0.5 days.

BioNxt Solutions Stock Up 2.5%

BNXTF stock traded up $0.02 during mid-day trading on Friday, reaching $0.67. The company had a trading volume of 450 shares, compared to its average volume of 2,432. The stock has a market capitalization of $77.87 million, a P/E ratio of -16.82 and a beta of 0.85. BioNxt Solutions has a one year low of $0.11 and a one year high of $0.80. The stock's 50-day simple moving average is $0.55 and its two-hundred day simple moving average is $0.43.

BioNxt Solutions (OTCMKTS:BNXTF - Get Free Report) last posted its earnings results on Thursday, August 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About BioNxt Solutions

BioNxt Solutions Inc engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains.